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Abstract
Background: NKG2D, an activating immunoreceptor, is primarily restricted to NK cells and CD8+ T cells. The
existence of an atypical cytotoxic CD4+NKG2D+ T cell population has also been found in patients with autoimmune
dysfunctions. Nonetheless, contradictory evidence has categorized this population with a regulatory rather than
cytotoxic role in other situations. These confounding data have led to the proposal that two distinct CD4+NKG2D+
T cell subsets might exist. The immune response elicited in cervical cancer has been characterized by apparent
contradictions concerning the role that T cells, in particular T-helper cells, might be playing in the control of the
tumor growth. Interestingly, we recently reported a substantial increase in the frequency of CD4+NKG2D+ T cells in
patients with cervical intraepithelial neoplasia grade-1. However, whether this particular population is also found in
patients with more advanced cervical lesions or whether they express a distinctive phenotype remains still to be
clarified. In this urgent study, we focused our attention on the immunophenotypic characterization of CD4+NKG2D+
T cells in patients with well-established cervical carcinoma and revealed the existence of at least two separate
CD4+NKG2D+ T cell subsets defined by the co-expression or absence of CD28.
Results: Patients with diagnosis of invasive cervical carcinoma were enrolled in the study. A group of healthy
individuals was also included. Multicolor flow cytometry was used for exploration of TCR alpha/beta, CD28,
CD158b, CD45RO, HLA-DR, CD161, and CD107a. A Luminex-based cytokine kit was used to quantify the levels
of pro- and anti-inflammatory cytokines. We found an increased percentage of CD4+NKG2D+ T cells in
patients with cervical cancer when compared with controls. Accordingly with an increase of CD4+NKG2D+ T
cells, we found decreased CD28 expression. The activating or degranulation markers HLA-DR, CD161, and
CD107a were heterogeneously expressed. The levels of IL-1beta, IL-2, TNF-alpha, and IL-10 were negatively
correlated with the percentages of CD4+NKG2D+ T cells in patients with cervical carcinoma.
Conclusions: Taken together, our results reveal the existence of two separate CD4+NKG2D+ T cell subsets
defined by the co-expression or absence of CD28, the latter more likely to be present in patients with
cervical cancer.
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Background
Why do some CD4+ T cells exhibit cytotoxic behav-
iour? This has been an important question deciphered,
in part, by the fact that these cells express activating
receptors mostly confined to lymphocytes, which by
nature are armed with a cytotoxic license [1–3]. More
recent evidence over the last years has revealed the
expression of a central innate cytotoxicity receptor on
a small population of CD4+ T cells; such is the case of
the immunoreceptor NKG2D [4–7]. This receptor is
highly conserved in primates and rodents, and its sym-
metric structure in humans consists of a homodimer
assembled to adaptor molecules, such as DAP10 [8, 9].
NKG2D/DAP10 signaling is facilitated via phosphatidyl-
inositol-3 kinase (PI3K), leading to the activation of mech-
anisms involved in cell survival, cytoskeletal rearrange-
ment, and release of cytotoxic granules [10–12]. That is
how NKG2D after recognizing a plethora of ligands,
which are for instance, largely up-regulated by actively
growing epithelial tumors, confers a significant activat-
ing (NK cells) or costimulating (cytotoxic T lympho-
cytes) signal to trigger the mechanisms already mentioned
above [13–17].
CD4+ T cells have been generally pre-defined as helpers
and regulators of the immune responses [18–20]. How-
ever a potential cytotoxic role within this population has
come to be discovered by the particular existence of an
unusual small subset comprised by CD4+ T cells that do
express NKG2D, which could represent a particular cyto-
toxic population involved in viral infections and chronic
diseases. At this point, Groh et al. reported a substan-
tial number of peripheral and synovial CD4+CD28− T
cells, which expressed the activating receptor NKG2D
in patients with rheumatoid arthritis; moreover, this
population promoted the cytotoxic damage against
synoviocytes with anomalous expression of NKG2D
ligands [21]. The existence of a large proportion of
CD4+NKG2D+ T cells has also been reported in HTLV-
1-associated neurologic disease, as well as in human
cytomegalovirus-seropositive individuals [4, 22]. Para-
doxically, it has also been reported the existence of a
normally-occurring CD4+NKG2D+ T cell population,
apparently endowed with regulatory activity in healthy
individuals, and interestingly the expansion of this
population appeared to be inversely correlated with
disease severity in patients with juvenile-onset systemic
lupus suggesting a regulatory rather than cytotoxic role
[23]. Furthermore, in other studies involving samples
from patients with different malignancies, it was noted
that a large proportion of CD4+NKG2D+ T cells with
regulatory activity was largely dependent of FasL and
NKG2D ligands [24], supporting the idea that an
immunosuppressive property distinguishes these cells
in some circumstances, such as cancer. The question,
which then arises, is whether this particular population
would be favouring an anti-tumor immune response, or
otherwise would be facilitating the tumor growth.
In particular, cervical cancer, which still remains as one
of the most common malignant tumors among women in
the developing world [25, 26], is predominantly controlled
by functional cellular immunity under the action of both
CD4+ and CD8+ T cells [27, 28]; however, these tumors
have been characterized by apparent contradictions in the
immune response [29–32], which could be partially ex-
plained by the action of specific CD4+ T cell subsets. All of
this is further complicated by the apparent existence of the
two functionally distinct CD4+NKG2D+ T cell subpopula-
tions, which could influence the fate of the anti-tumor im-
mune response, that is, to support cytotoxicity versus
immunoregulation or vice versa. Compelling evidence
by our group recently demonstrated an increase of
CD4+NKG2D+ T cells in patients with low-grade cervical
lesions, even when overall levels of CD4+ T cells did not
increase. Also, in that study it was found that while TGF-
β1 was significantly decreased in patients compared to
healthy donors, both TNF-α and IL-15 showed a tendency
to increase [33]. Thus, with these findings we believe that
the expansion of CD4+NKG2D+ T cells in premalignant
cervical lesions might be under the control of factors that
are not well characterized at the moment, and that this
population might be also expanded in established cancer-
ous lesions of uterine cervix. However, the immunopheno-
typic signature characterizing these cells in cervical cancer
patients has not yet been well defined. Therefore, the
focus of our present work was to determine whether the
population of NKG2D-expressing CD4+ T cells is also in-
creased in invasive cervical carcinoma and to characterize
the phenotypic profile of this particular population.
Our present results reveal the existence of two separate
CD4+NKG2D+ T cell subsets defined by the co-expression
or absence of CD28, which might indicate a functional di-
chotomy within this particular subset. On the other hand,
the negative and significant correlation between the levels
of IL-1β, IL-2, TNF-α, and IL-10 and the percentages of
CD4+NKG2D+ T cells might suggest that increased
levels of these cells are more likely to be present in
anti-inflammatory environments in patients with cer-
vical cancer.
Methods
Patients and healthy donors
We recruited 31 patients that were first subjected to
conventional colposcopic evaluation and finally diag-
nosed as invasive squamous cervical carcinoma by
histopathology results. Thirty-one age/gender matched
healthy donors without histories of abnormal Pap
smears were included. All patients were attended at the
Instituto Jalisciense de Cancerología, OPD (Guadalajara,
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México) and Centro Médico Nacional de Occidente, IMSS
(Guadalajara, México). Prior to be enrolled, the purpose
and procedures of the study were explained to patients and
informed consent was obtained from each patient or
healthy control. Clinical and epidemiological features were
also obtained.
Ethical considerations
All samples were acquired according to the guidelines of
the Ethics Committee of the Centro Universitario de Cien-
cias de la Salud, Universidad de Guadalajara (Guadalajara,
Mexico), in accordance with the official guidelines (Norma
Oficial Mexicana, NOM) and the World Medical Associ-
ation Declaration of Helsinki. All women were informed of
their rights, the goals of the study, and the importance of
their participation. The procedures used for collection of
samples were identical to those routinely used in the clin-
ical setting and used for patients not being part of this
study.
Collection of specimens
Five mL of peripheral blood (PB) was collected in
tubes containing EDTA buffer and processed for multi-
color flow cytometry analyses within 2 h after arrival at
the laboratory. The remaining peripheral blood was
centrifuged at 300 g for 15 min in order to obtain the
plasma, which was stored at –70 °C until processing by
ELISA assays.
Antibodies
Fluorochrome-labeled monoclonal primary antibodies
for simultaneous multi-antibody staining were pur-
chased from BioLegend Inc. (San Diego, CA, USA)
and the list included: PE/Cy7 anti-human CD3 (clone
UCHT1), PerCP/Cy5.5 anti-human CD4 (clone RPA-T4),
PE anti-human NKG2D (clone 1D11), APC anti-human
CD28 (clone CD28.2), APC anti-human TCR αβ (clone
IP26), APC anti-human TCR Vα24Jα18 (iNKT cell) (clone
6B11), APC anti-human CD107a (clone H4A3), FITC anti-
human CD158b (clone DX27), FITC anti-human CD45
RO (clone UCHL1), FITC anti-human CD161 FITC (clone
HP-3G10), FITC anti-human HLA-DR (clone L243). Iso-
type control antibodies were also purchased from BioLe-
gend Inc.
Immunophenotyping of CD4+NKG2D+ T cells by
multicolor flow cytometry
Multicolor flow cytometric analysis was performed to de-
tect the frequency and immunophenotypic profile of the
CD4+NKG2D+ T cell population. Assay tubes with 100 μL
of freshly isolated whole blood from cervical cancer pa-
tients or healthy controls was stained with a mixture of
the corresponding antibodies for 45 min at 4 °C. After in-
cubation, erythrocytes were lysed using BD FACS Lysing
Solution (BD Bioscience, San Jose, CA, USA). The expres-
sion of TCR αβ, TCR Vα24Jα18, CD28, CD45RO,
CD158b, CD107a, CD161 and HLA-DR was detected on
the gate drawn around the CD3+CD4+NKG2D+ lympho-
cyte population. Firstly, lymphocytes were distinguished
from other mononuclear cells using morphological pa-
rameters. Then, gate was drawn around the lymphocyte
population, which was then analyzed separately using the
labeling antibody scheme. Attune® NxT Acoustic Focusing
Cytometer (Life Technologies, Carlsbad, CA, USA) was
used to acquire twenty thousand events in the lymphocyte
region. FACS data were analyzed using FlowJo software,
version 8.7 (Tree Star, Inc., Ashland, OR, USA).
Cytokine quantification
A commercial magnetic bead-based immunoassay (Bio-
Rad Laboratories Inc., Hercules, CA, USA) enable to
quantify multiple cytokines in a single well was used to
quantify the cytokines in plasmas from cervical cancer
patients or control women. Briefly, we designed a kit,
which included the detection of pro- and anti-
inflammatory cytokines: IL-15, IL-1β, IL-6, IL-17, TNF-α,
IFN-γ, IL-2, and IL-10. Thawed samples, standard dilution
series, and blanks were pipetted into designated wells; then
plate was incubated at RT for 30 min, at 300 rpm shaking
to enhance detection assay. After a series of washes to re-
move unbound protein, a biotinylated detection antibody
was added to create a sandwich complex. The final detec-
tion complex was formed with the addition of streptavidin-
phycoerythrin conjugate. Data were acquired using a
Bio-plex system reader and management of results was
performed using Bio-Plex Data Pro software.
Statistical analysis
All data were tested for normal distribution using
Kolmogorov-Smirnov test. Due to non-normal distri-
bution Mann–Whitney U-test was used to compare
two groups of analysis (healthy donors vs cervical can-
cer patients). Based on our previous results we strati-
fied our present results in three different ranges (0–2,
2–4, and >4 % of CD4+NKG2D+ T cells). Correspond-
ing to these ranges, results of CD4+NKG2D+ T cells
were tested using Pearson’s chi-square test and data
were expressed as percentage of frequency. According
to this stratification we performed a subsequent ana-
lysis to evaluate the expression of different markers
expressed by CD4+NKG2D+ T cells. In order to
measure statistical dependence between the variables,
Spearman’s rank correlation coefficient was used. All
the statistical analyses were performed considering
p ≤ 0.05 to be significant using SPSS 15.0 software
(SPSS, Chicago, IL, USA).
Garcia-Chagollan et al. Journal of Biomedical Science  (2015) 22:91 Page 3 of 12
Results
High numbers of CD4+NKG2D+ T cells are circulating in
patients with established cervical carcinoma
We have previously reported an increase of CD4+NKG2D+
T cells in patients with low-grade cervical intraepithelial
neoplasia, which might be the result of a chronic exposure
to viral and/or pro-inflammatory factors [33]. In this con-
text, different groups have addressed the effect of host
pro-inflammatory responses in human papillomavirus
(HPV)-related diseases [29, 34], which might promote
lesion progression to more advanced stages and affect
tumor fate by diverse mechanisms including the direct
participation of unusual immune cells, as would be the
case of the CD4+NKG2D+ T cells. Here, we wanted to
focus our attention and search for this T cell popula-
tion in peripheral blood from patients with cervical
carcinoma. Thirty-one patients with established histo-
pathological diagnosis of invasive squamous cervical
carcinoma were enrolled in this study (ages ranged
from 31–77 years, with a mean age of 51.45 years);
additionally, a control group of 31 donors matched in
age/gender was also included (ages ranged from 38–70
years with a mean age of 50.19 years). First, lympho-
cytes were gated according to their forward scatter
(FS) and side scatter (SS) characteristics. Then, further
gates were placed around those CD3+ and CD4+ T
cells, and subsequently the NKG2D expression was
evaluated. Based on our own results and also reported
by others [5, 33], we have frequently seen that the
CD4+NKG2D+ T cell population is not higher than 2 %
in healthy controls, and that expansions of this popula-
tion are often seen in patients with premalignant
cervical lesions. Taking into account these data, we
stratified our current results in three different ranges
of CD4+NKG2D+ T cells (0–2, 2–4, and >4 %). Patient
samples were significantly more likely to have higher
levels of CD3+CD4+NKG2D+ T cells than control sam-
ples. While present to some extent in all samples tested,
the distribution of this particular T cell population is sig-
nificantly increased in cervical cancer patients (χ2(2) =
6.531; p = 0.038). In Fig. 1a we see that some 68 % of
the different control samples expressed very low
CD4+NKG2D+ T cells (0–2 %). Only 13 % of the con-
trol samples expressed CD4+NKG2D+ T cells above the
level of 4 %, while 39 % of cervical cancer patient samples
had levels of 4 % or greater of these cells. A representative
example of this disparity is shown in Fig. 1b, where 18 % of
the cancer patient’s CD3+CD4+ T cells are positive for
NKG2D (lower panel), while only 1.4 % of the healthy con-
trol’s CD3+CD4+ T cells show this staining (upper panel).
Circulating CD4+NKG2D+ T cells in patients with
established cervical cancer express the conventional TCR
αβ+ heterodimer
Given that invariant NKT cells can be defined by
phenotype, e.g. CD4+ vs CD4− [35], it is possible that
Fig. 1 Frequency of circulating CD4+NKG2D+ T cells in patients with established cervical carcinoma. Multicolor flow cytometric analysis
was performed to measure the expression of NKG2D on peripheral CD4+ T cells from both healthy donors and cervical cancer patients.
Lymphocytes were gated according to FS and SS characteristics and sub-gated around CD3+ and CD4+ T cells; subsequently, NKG2D
expression was evaluated. Bars in (a) represent the distribution of samples with varying levels of CD4+NKG2D+ T cells within the control
and patient groups. Based on previous results, here our data were stratified in three different ranges of CD4+NKG2D+ T cells (0–2, 2–4,
and >4 %). A significant increase in the frequency of CD4+NKG2D+ T cells in the group of cervical cancer patients was found, while some
68 % of the different control samples expressed very low CD4+NKG2D+ T cells (0–2 %) (χ2(2) = 6.531; p = 0.038). A representative example
of this disparity is shown in (b), where 18 % of the cancer patient’s CD3+CD4+ T cells are positive for NKG2D (lower panel), while only
1.4 % of the healthy control’s CD3+CD4+ T cells show this staining (upper panel)
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CD4+ NKT cells may be expanded within the total
CD4+NKG2D+ T cell population. Similar to NKT cells,
other unconventional innate-like cells, such as γδ T
lymphocytes may also contribute to the total pool of T
cells expressing the immunoreceptor NKG2D. Thus, in
order to discard the possibility that the triple positive
CD3+CD4+NKG2D+ cells observed were either γδ T
cells or invariant NKT cells, we stained with antibodies
specific for αβ TCR and Vα24Jα18 TCR α chain. Figure 2a
shows a representative sample in which the double
positive CD3 and CD4 lymphocyte population was
sub-gated based on NKG2D expression. Then, the
expression of αβ TCR and Vα24Jα18 TCR α chain was
explored. As expected, we found that greater than 95 % of
the CD3+CD4+NKG2D+ cells were TCR αβ+ (Fig. 2b) and
fewer than 2 % of these cells were positive for the com-
mon invariant chain Vα24Jα18 (Fig. 2c). The blood from
the control samples tended to have almost double the
amount of invariant chain positive cells, but this result
was not significant.
CD28 costimulatory receptor defines the existence of
different CD4+NKG2D+ T cell populations in established
cervical carcinoma
In human CD8+ T cells, it has been reported that the
immunoreceptor NKG2D serves as a costimulatory plat-
form for TCR-mediated signaling through the recruitment
of the p85 regulatory subunit of PI3K, in a manner similar
to CD28 [15]. Recently, a functional dichotomy for both
CD28 and NKG2D in distinct CD8+ T cells has been
noted [36, 37]. In our current work, we find that, within
the CD3+CD4+NKG2D+ T cell gate, it is the presence or
absence of CD28 that defines at least two cell populations,
both present in patient and control samples. CD28
Fig. 2 CD4+NKG2D+ T cells express the conventional TCR αβ in both healthy donors and cervical cancer patients. Multicolor flow cytometry
analysis was performed in order to discard that the triple positive CD3+CD4+NKG2D+ T cells were either γδ T cells or iNKT cells. In (a) we show
a representative example of high percentage of CD4+ T cells expressing NKG2D in a cervical cancer sample. Following multicolor staining
to detect CD3 expression and CD4 co-expression, NKG2D was evaluated. Then, expression of TCR αβ and Vα24Jα18 (in order to know
whether they represented a population of iNKT cells) was measured on the triple positive CD3+CD4+NKG2D+ T cell population. In (b) we
show the distribution of TCR αβ on CD4+NKG2D+ T cells in controls and cervical cancer patients. More than 95 % of the CD3+CD4+NKG2D+
T cells were TCR αβ+ in both controls and cervical cancer patients. Distribution of TCR Vα24Jα18 on selected CD3+CD4+NKG2D+ T cells in
controls and cervical cancer patients is shown in (c), which indicates that CD3+CD4+NKG2D+ T cells were mostly negative to Vα24Jα18 in both
groups. Data are expressed as mean ± SEM
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expression was evaluated on selected lymphocytes, which
were previously gated on CD3 and CD4 double-positive
cells, and then sub-gated on NKG2D co-expression as
shown in Fig. 3a, which depicts representative analyses of
these measurements.
We see that many of the patient and control samples
had a substantial percentage of cells that were positive
for CD28 (Fig. 3b), but when focusing on the samples
with higher CD4+NKG2D+ T cell percentages, this num-
ber was much lower in both populations. It is interest-
ing, however, to focus further on the differences between
the populations in aggregate. We see a significant differ-
ence between patient and control samples with control
CD4+NKG2D+ T cells significantly more likely to express
CD28 (Mann–Whitney U-test; p = 0.008). Within the
patient samples, the loss of CD28 was sharply evident in
the samples that had higher levels of CD4+NKG2D+ T
cells. When the patient and control samples were again di-
vided into groups based on percentage of CD4+NKG2D+ T
cells (Fig. 3c), we continued to see this division, with the
loss of CD28 in both patients and controls that have high
numbers of CD4+NKG2D+ T cells. Negative and statisti-
cally significant correlations between CD28 expression and
percentages of CD4+NKG2D+ T cells were observed in
both cancer patients (Spearman ρ = -0.859; p < 0.001) and
healthy controls (Spearman ρ = -0.522; p = 0.003).
Fig. 3 CD28 expression defines two different populations of CD4+NKG2D+ T cells in cervical cancer patients. Flow cytometry analysis of
multicolor staining was performed in order to detect the expression of CD28 on selected CD3+CD4+NKG2D+ T cells. In (a) representative
experiments show the expression of CD28 in a control sample with low percentage of CD4+NKG2D+ T cells (upper panel) and cancer sample
with high percentage of CD4+NKG2D+ T cells (lower panel). In (b) we see a significant difference between patient and control samples with
control CD4+NKG2D+ T cells significantly more likely to express CD28 (Mann–Whitney U-test; p = 0.008). In (c) patient and control samples were
divided into groups based on percentage of CD4+NKG2D+ T cells and we see a division, with the loss of CD28 in both patients and controls that
have high numbers of CD4+NKG2D+ T cells. Negative and statistically significant correlations between CD28 expression and percentages
of CD4+NKG2D+ T cells are seen in both control (Spearman ρ = -0.522; p = 0.003) and patient (Spearman ρ = -0.859; p < 0.001) groups
when segregated based on percentage of CD4+NKG2D+ T cells
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Degranulation and cytotoxic markers tend to diminish in
CD4+NKG2D+ T cells which are negative for the
costimulatory CD28 molecule
Focusing on what appears to be a unique population of
CD4+NKG2D+CD28− T cells that are overrepresented
in, but not exclusive, to cervical cancer patients, cells
from samples with high (>4 %) levels of CD4+NKG2D+
T cells were found to be essentially negative and very
low for the presence of the markers CD107a and
CD161, respectively. Expression of CD107a and CD161
was graphed as a percentage of gated CD4+NKG2D+ T
cells in control and cervical cancer groups subdivided,
in turn, into the three groups based on ranges of
CD4+NKG2D+ T cell percentages, which were charac-
terized by the expression or lack of CD28 (Fig. 4a
and b, respectively). Negative and statistically signifi-
cant correlations were found in accordance with the
increase of CD4+NKG2D+ T cells and the decrease of
CD107a (Spearman ρ = -0.480; p = 0.006) and CD161
(Spearman ρ = -0.441; p = 0.013) expression in healthy
donors. Negative correlation in cervical cancer was
not significant; however, a similar tendency to that
seen in healthy donors was also observed. Figure 4c de-
picts representative FACS dot plots of the expression of
CD107a and CD161 on the gated CD3+CD4+NKG2D+ T
cell population in a sample from a control (upper panel)
or cancer patient (lower panel). The expression of these
cytotoxic markers is clearly lost in accordance with the
increase of the CD4+NKG2D+ T cell population. Con-
tinuing this analysis with other immunophenotypic
markers, additional molecules were also evaluated
within the gated CD3+CD4+NKG2D+ T cells. Particu-
larly, a broad distribution of the CD45RO isoform in
samples from control donors or patients, irrespective of
the levels of CD4+NKG2D+ T cells, was seen (data not
shown). Surface HLA-DR molecule, which is expressed
de novo within the activation process of T cells, was
heterogeneously expressed by CD4+NKG2D+ T cells
from both control and patient groups (data not shown).
CD158b, which is typically confined to NK cells (or
some CD8+TCRαβ+ effector T cells), appeared to be
mainly expressed in CD4+NKG2D+ T cells when this
population was underrepresented (range 0–2 %) in both
control and cervical cancer groups (data not shown).
Plasma levels of pro-inflammatory cytokines are significantly
diminished in cervical cancer patients
Pro-inflammatory cytokines may stimulate the cell surface
expression of NKG2D on CD4+ T cells [21]. With circu-
lating CD4+NKG2D+ T cells frequently expanded in
patients with cervical cancer, we wanted to explore
the plasma cytokine profile, including pro- and anti-
inflammatory cytokines, which may be involved in
the expansion of this particular T cell population.
Once again, control and cervical cancer groups were di-
vided into the three different ranges of CD4+NKG2D+ T
cells (0–2, 2–4, and >4 %). Interestingly, plasma levels of
pro-inflammatory cytokines IL-1β (Fig. 5a), TNF-α (Fig. 5b),
and IL-2 (Fig. 5c) were significantly and negatively corre-
lated with the numbers of CD4+NKG2D+ Tcells in cervical
cancer samples (IL-1β: Spearman ρ = -0.408; p = 0.023;
TNF-α: Spearman ρ = -0.394; p = 0.028; IL-2: Spearman ρ
= -0.522; p = 0.003). Despite the fact that we did not find
any significant correlation in control samples, a similar
trend was seen as well, with the lowest values of pro-
inflammatory cytokines occurring when the CD4+NKG2D+
T cell population was overrepresented (also shown in
Fig. 5a, b, and c). In Fig. 5d it is notable that the cytokine
IL-10, which is commonly considered as anti-inflammatory
cytokine, was also negatively correlated in patient samples
in accordance with the increases of CD4+NKG2D+ T cells
(Spearman ρ = -0.414; p = 0.021). This same tendency was
found in control samples, although the values were not
statistically significant. Additionally, we also measured the
levels of the pro-inflammatory cytokines IL-15, IL-6,
IL-17, and IFN-γ, which were found to be diminished in
cervical cancer patients in accordance with the expansion
of the CD4+NKG2D+ T cell population; however, no
statistically significant correlation was found in control or
patient samples (data not shown).
Discussion
The existence of unusual cytotoxic CD4+NKG2D+ T
cells have been reported in individuals with chronic
inflammatory diseases or viral infections [21, 22]; how-
ever, opposing evidence has implicated the existence of
a normally-occurring CD4+NKG2D+ T cell population
apparently endowed with regulatory activity in healthy
individuals, and interestingly appeared to be inversely
correlated with disease severity in patients with
juvenile-onset systemic lupus erythematosus [23].
These confounding data lead to the speculation that
two distinct CD4+NKG2D+ T cell subsets might be op-
erating in different disease settings. Our group recently
showed that in patients with cervical intraepithelial
neoplasia grade-1 (CIN-1), there is an atypical expan-
sion of circulating CD4+NKG2D+ T cells, which could
be the result of a chronic exposure to viral and/or pro-
inflammatory factors, and that this expansion might
perhaps affect the fate of the lesion [33]. In order to ex-
tend that result to patients with more advanced stages
of cervical lesions, we included in the present work a
group of patients who were diagnosed histopathologic-
ally as having invasive squamous cervical carcinoma.
We first stratified our results in three different ranges
of CD4+NKG2D+ T cells (0–2, 2–4, and >4 %), as we
previously saw that this population was not higher than
2 % in healthy controls and was increased in patients with
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CIN-1 (in average 3.6 % of CD4+NKG2D+ T cells) [33]; in
fact, amounts still greater than 4 % were generally found
in patients with persistent/recurrent disease (unpublished
data). Interestingly, while only 13 % of the control samples
expressed CD4+NKG2D+ T cells above the level of 4 %, a
much higher percentage (39 %) of cervical cancer patients
had levels of 4 % or greater of these cells. Certainly, the
sole infection with HPV could explain, in part, the fre-
quent expansion of CD4+NKG2D+ T cells seen in the can-
cer patients; however, we did not test for the presence of
the virus (unlike our study with CIN-1 patients), since it is
well known that virtually all cervical carcinoma patients
(99.7 %) have shown to be HPV-DNA carriers [38].
Lack of the costimulatory molecule CD28 on CD4+ T
cells has been reported in some chronic inflammatory
diseases and elderly individuals [39–41]. Particularly,
patients with advanced cervical cancer have exhibited a
markedly reduced proportion of CD28+ cells within both
CD4+ and CD8+ T cell subpopulations [42]. Perhaps one
of the most striking findings in our analysis has been the
fact that CD28 defines unique populations within the
already rare and incompletely characterized CD4+NKG2D+
Fig. 4 Degranulation and cytotoxic markers are diminished in CD4+NKG2D+CD28− T cells. Expression of the degranulation (CD107a) and cytotoxic
markers (CD161) was measured on gated CD3+CD4+NKG2D+ T cells in control and cervical cancer samples subdivided in turn, into the three
groups based on ranges of CD4+NKG2D+ T cells (as mentioned in Results). Expressions of CD107a (a) and CD161 (b), graphed as a percentage of
gated CD4+NKG2D+ T cells, were negative and statistically significant correlated accordingly with the expansion of CD4+NKG2D+ T cells
(Spearman ρ = -0.480; p = 0.006; Spearman ρ = -0.441; p = 0.013, respectively) in control samples. Negative correlation in cervical cancer was not
significant; however, a similar tendency to that seen in healthy donors can be also observed. Representative FACS dot plots of CD107a and
CD161 expression in control (upper panel) or cancer patient (lower panel) are shown in (c). The expression of these markers is clearly lost in
accordance with the increase of the CD4+NKG2D+ T cell population
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T cell population. The results shown in Fig. 3 suggest that
when CD4+NKG2D+ T cells are expanded a unique CD28−
population predominates. If we mainly focus on cervical
cancer samples, we find at least two types of patients, one
with an expanded population of CD4+NKG2D+ T cells and
one without. In the patients with expanded populations of
CD4+NKG2D+ T cells, the CD28− phenotype predomi-
nates. Given the relative numbers of these cells in the dif-
ferent patient groups, it is difficult to say if the patients
with the expanded CD4+NKG2D+ T cells have converted
the CD28+ cells to a negative phenotype, or if there is an
expansion of other cells that simply dwarfs the absolute
number of CD28+ cells seen in the patients with low
CD4+NKG2D+ T cells. The intermediate group (2–4 % of
CD4+NKG2D+ T cells) might be simply an overlapping
mixture of both CD28+ and CD28− cells. Interestingly, the
same behavior was observed in samples from controls,
where we can distinguish carrier and non-carriers of
CD28 on the selected CD4+NKG2D+ T cell population;
this finding indicates that there might exist a functional
dichotomy within these subsets. Interestingly, CD4+CD28−
T cells have been frequently found in patients with
autoimmune disorders and other chronic infectious dis-
eases and it has been found that these cells are essential
producers of cytolytic molecules, such as perforin and gran-
zyme B [43–45]. In this current work, we did not identify
intracellular cytolytic molecules; thus, it will be necessary to
design further experiments in order to prove if these mole-
cules are distinctive signature in any of the different CD4
+NKG2D+ T cell populations, which may or may not ex-
press the costimulatory marker CD28.
In the search for immunoregulation-associated molecu-
lar markers we have interestingly found, in current
ongoing experiments, in selected CD4+NKG2D+ T cells
from healthy donors (with ranges between 0 and 2 % or
>4 %), that there is a discrepancy regarding the expression
of the master transcription factor Foxp3, with prefer-
ential expression on those T cells co-expressing both
NKG2D and CD28. This suggests that a possible natural
CD4+NKG2D+CD28+ T cell population, mostly found in
healthy individuals, is endowed with immunoregulatory
functions and that this regulatory role becomes altered
when the population expands in pathological conditions
associated with chronic inflammation, such as occurs in
Fig. 5 Plasma levels of pro-inflammatory cytokines are significantly diminished in cervical cancer patients. Using a commercial magnetic bead-based
immunoassay, multiple cytokines were quantified in plasmas from cervical cancer patients or control women. Here again, control and cervical cancer
groups were divided into the three different ranges of CD4+NKG2D+ T cells (0–2, 2–4, and >4 %). Systemic levels of IL-1β (a), TNF-α (b), and IL-2 (c)
negatively correlated with the number of CD4+NKG2D+ T cells in cervical cancer patients (IL-1β: Spearman ρ = -0.408; p = 0.023; TNF-α: Spearman
ρ = -0.394; p = 0.028; IL-2: Spearman ρ = -0.522; p = 0.003). The cytokine IL-10 was also negatively correlated in patient samples, accordingly with the
increase of CD4+NKG2D+ T cells (Spearman ρ = -0.414; p = 0.021), as shown in (d)
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the case of uterine cervical cancer. More studies will be
necessary, however, in order to demonstrate the lack of
Foxp3 in expanded CD4+NKG2D+ T cells from cervical
cancer patients.
Searching for markers to define the CD4+NKG2D+
T cell population further, we examined CD161 and
CD107a. Looking deeper at this immunophenotyping,
we found that the lowest levels of these cytotoxicity
or degranulation markers were commonly found in
samples with high CD4+NKG2D+ T cell levels. A dis-
tinction between samples from controls and patients was
seen with CD161 staining where the patient samples with
high CD4+NKG2D+ T cell levels expressed CD161 three
fold higher than the high CD4+NKG2D+ T cell level from
the controls. This may indicate the presence of activated
pro-inflammatory cells (possibly Th17) in the cervical can-
cer patients. This idea may be plausible if we were to take
into account that there is a recent report showing that
CD4+NKG2D+ T cells represent a key source of IL-17 in
patients with Crohn’s disease and that these cells share a
Th17-related phenotype, including high expression of the
cytotoxicity marker CD161 [6]. However, we may pos-
sibly have to discard this possibility due to the fact that
in our analysis the lowest levels of systemic IL-17 were
actually found in cervical cancer patients with high
numbers of CD4+NKG2D+ T cells (data not shown);
however, we will clearly need more studies to specific-
ally detect the cytokine pattern produced by this par-
ticular population of CD4+NKG2D+ T cells in cervical
cancer patients. In continuing with this and given the
heterogeneity of the cancer patient group, it is not sur-
prising that a few outlier samples expressed relatively
high levels of CD107a and CD161. Interestingly, the pa-
tients that expressed starkly higher levels of CD107a (four
patients) all had very low levels of CD4+NKG2D+ T cells,
and three of these patients were among the five highest
outliers for CD161 as well, suggesting a distinct, perhaps
more cytotoxic, immune response in these patients.
On the other hand, the wide distribution of the CD45RO
isoform in samples from control and patients, irrespectively
of the levels of CD4+NKG2D+ T cells (data not shown),
suggests a memory and/or activated state on this particular
T cell population. This result is not surprising if we con-
sider that the repetitive exposure to the same antigen
seems to be a cause for NKG2D expression [4, 46];
thus, it would be reasonable to expect a memory/effector
state in the CD4+NKG2D+ T cell pool. Other markers, as
HLA-DR or CD158b, were heterogeneously expressed
by CD4+NKG2D+ T cells from both controls and pa-
tients (data not shown), which might indicate different
activation/differentiation stages within the lifespan of
the CD4+NKG2D+ T cells.
Cytokine-mediated regulation of NKG2D in CD4+ T
cells has not yet been fully understood, but, at least,
there is also evidence concerning the influence of pro-
inflammatory cytokines on NKG2D induction; one ex-
ample is a report showing that a substantial number of
peripheral and synovial CD4+CD28− T cells in patients
with rheumatoid arthritis expressed NKG2D under the
influence of IL-15 and TNF-α, which endowed this T cell
population with cytotoxic activity and the ability to lyse
synoviocytes aberrantly expressing NKG2D ligands [21].
In our current work, however, we did not find high
levels of IL-2 or TNF-α in those patients (or controls)
with expanded CD4+NKG2D+ T cells; on the contrary,
significant and negative correlations between the num-
bers of CD4+NKG2D+ T cells and levels of these pro-
inflammatory cytokines were found in cervical cancer
samples. At a first glance, this would seem paradoxical if
we consider that a pro-inflammatory environment ought
to act in favor of NKG2D expression; however, taking into
consideration our preliminary results from ongoing re-
search in healthy donors with respect to the preferential
expression of Foxp3 in those CD4+NKG2D+ T cells, which
in turn co-express CD28, and usually seen in the lowest
range of 0–2 % (as already mentioned), it might indi-
cate a functional divergence among the apparently dif-
ferent subsets of CD4+NKG2D+ T cells.
The negative correlation also found between the plasma
concentrations of IL-1β and numbers of CD4+NKG2D+ T
cells in cancer patients may simply be an independent
variable resulting from the fact that IL-1β is typically
activated in situations where TNF-α is produced. Des-
pite the fact that we did not find significant correla-
tions in the control group, it is important to remark
that the same tendency was also observed. Data re-
lated to IL-10 are not surprising if again we consider
that a hyper-secretion of this anti-inflammatory cyto-
kine would act to regulate the production of pro-
inflammatory mediators. Indeed, it has been proposed
that a normally occurring CD4+NKG2D+ T cell population
is tasked with the production of IL-10 and FasL and is in-
versely correlated with disease activity in juvenile-onset
lupus [23]. Apparently, this particular T cell population,
with regulatory rather than cytotoxic role, might be
different than that previously described in other auto-
immune disorders, such as rheumatoid arthritis [21].
However, our current study is limited by the fact that nei-
ther the cytokine profile yielded by the different subsets of
CD4+NKG2D+ T cells (characterized by the expression or
lack of CD28) was evaluated, nor the effect of exogenous
pro-inflammatory cytokines on these cells was assessed;
thus, these experiments should be planned in the future
to truly reveal the meaning of the balance between
CD4+NKG2D+CD28+ T cells and CD4+NKG2D+CD28− T
cells and to answer whether the CD4+NKG2D+ T cell
population frequently seen in our patients promotes or
discourages the growth of cervical cancer.
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Conclusions
Taken together, our results reveal the existence of two
separate CD4+NKG2D+ T cell subsets defined by the co-
expression or absence of CD28, the latter more likely to
be present in anti-inflammatory environments and in pa-
tients with cervical cancer.
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